ctDNA testing effectively stratifies Merkel cell carcinoma patients into high and low recurrence risk categories, influencing surveillance strategies. The study's cohorts revealed significant ...

They show that just over 90% of muscle invasive bladder cancer (MIBC) patients with a negative circulating DNA (ctDNA) test following surgery, which remained negative on follow up, did not relapse.

Natera has announced the use of its Signatera molecular residual disease (MRD) test in a breast cancer trial, TREAT ctDNA, which will assess oral endocrine monotherapy elacestrant (Orserdu).

The results of a ctDNA test can be therapeutic. Two-thirds of cancer survivors suffer from fear of cancer recurrence (FCR) making it the most common long term complication from a cancer diagnosis.

The largest study to date to assess the clinical value of concurrently testing tissue and circulating tumour DNA (ctDNA), highlights the usefulness of this dual approach for identifying targetable ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

AstraZeneca is working with Qiagen to develop a circulating tumour DNA (ctDNA) test to identify non-small cell lung cancer (NSCLC) patients whose tumours are EGFR mutation positive, and who may be ...

The studies will evaluate the use of circulating tumour DNA (ctDNA) in monitoring treatment response in breast cancer patients. The Precise MRD test is a genome sequencing (WGS) based test that ...

Most of the currently available circulating tumor DNA (ctDNA) technologies provide a high level of diagnostic accuracy for detecting human papillomavirus (HPV)-associated oropharyngeal squamous ...

The U.S. FDA recently approved the Itovebi-based regimen as a first-line treatment for people with HR+, Her2-negative breast cancer with PIK3CA mutations. The PredicineCARE™ blood ctDNA assay played ...